Pretax income is the income that a company earns before paying income taxes. Kaken Pharmaceutical Co's pretax income for the
three
months ended in Dec. 2023 was 円3,562 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was 円3,396 Mil.
Kaken Pharmaceutical Co's pretax margin was 19.24%.
During the past 13 years, Kaken Pharmaceutical Co's highest Pretax Margin was 32.31%. The lowest was 4.71%. And the median was 25.68%.
Kaken Pharmaceutical Co Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kaken Pharmaceutical Co's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's Pre-Tax Income falls into.
Kaken Pharmaceutical Co Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Kaken Pharmaceutical Co's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,396 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (TSE:4521) Pre-Tax Income Explanation
Kaken Pharmaceutical Co's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Kaken Pharmaceutical Co's highest Pretax Margin was 32.31%. The lowest was 4.71%. And the median was 25.68%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Kaken Pharmaceutical Co (TSE:4521) Business Description
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4521 has been successfully added to your 